Novo Nordisk’s third-quarter 2026 sales rose 4% at constant exchange rates to DKK 79.2 billion, helped by DKK 5.4 billion from the Wegovy pill in its third quarter on the market. The company raised its full-year outlook for a third time, to adjusted sales and operating profit growth of between -2% and +2%.
Global Economy Charts Research Desk | November 8, 2026
Key indicators
| Indicator | Reading | Context |
|---|---|---|
| Q3 sales | DKK 79.2bn | +6% reported, +4% at constant exchange rates |
| Q3 adjusted operating profit | DKK 31.7bn | +27% CER; reported DKK 23.0bn (-9% CER) |
| Wegovy pill sales, Q3 | DKK 5.4bn | Reuters poll: DKK 4.62bn; launched January 2026 |
| 2026 outlook (adjusted, CER) | -2% to +2% | Previously -6% to 0% for sales and operating profit |
| Free cash flow outlook | DKK 60-70bn | Previously DKK 45-55bn |
Growth came almost entirely from obesity care, where sales rose 22% at constant exchange rates to DKK 26.1 billion, while diabetes sales fell 5% to DKK 47.5 billion. Adjusted operating profit benefited from a low base: the third quarter of 2025 included about DKK 9 billion of transformation costs. Reported profit was cut by DKK 8.7 billion of impairments this year.
1. The pill offsets injectable weakness
Wegovy pill sales of DKK 5.4 billion beat the DKK 4.62 billion expected in a Reuters poll, with about DKK 4.2 billion coming from the US. Reuters reported about 3.6 million US prescriptions in the quarter. Injectable Wegovy sales were flat in kroner and fell 2% at constant rates, and Reuters said US injectable sales dropped 13%. Combined US Wegovy sales, including the pill, rose 21%.
2. International markets outgrow the US
Sales in the US rose just 1% at constant exchange rates to DKK 41.9 billion, as realised prices fell, partly because of a most-favoured-nation pricing agreement. International Operations grew 8% to DKK 37.3 billion, led by Europe and Canada at 18%. Sales fell 5% in China and 7% in the rest of the Asia-Pacific region. Ozempic, still the largest product, fell 5% at constant rates.
3. A third upgrade, with caveats
Novo now expects adjusted sales and operating profit to change by between -2% and +2% at constant exchange rates in 2026, up from -6% to 0% in August and -12% to -4% in May. Reported growth in kroner is now expected to be in line. Free cash flow guidance rose to DKK 60-70 billion and capital spending was cut to about DKK 50 billion. Reuters said 2027 guidance will come in February.
4. Price cuts ahead and Lilly competition
From 1 January 2027, Novo will cut US list prices for Wegovy and Ozempic to $675 a month, about 50% and 35% lower respectively, which it says will weigh on 2027 cash flow. Reuters noted that Eli Lilly raised its own outlook a week earlier and that Lilly’s Zepbound outsells injectable Wegovy. Novo’s shares rose as much as 6.6% on results day, but remain more than 70% below their 2023 peak.
Scenarios to watch
If Wegovy pill prescriptions keep growing at recent rates, oral treatments could offset falling prices for injectables and support a return to growth. If the January list-price cuts reduce net revenue faster than volumes rise, 2027 could bring renewed pressure on margins. February’s 2027 guidance, Lilly’s oral-drug uptake and US pricing policy are the main signals to watch. These are scenarios for monitoring, not forecasts or investment advice.
Sources and methodology
Novo Nordisk, financial report for the first nine months of 2026 (Form 6-K), 4 November 2026; Novo Nordisk, outlook raise, 4 August 2026; Reuters via TimesLIVE, 4 November 2026; Reuters via Devdiscourse, 4 November 2026; CNBC, 4 November 2026. Reported figures are distinguished from forecasts and GEC calculations. Charts use the values and units shown; scales start at zero except where negative values or index thresholds require otherwise. Interpretive sections are GEC analysis, not company or central-bank forecasts.
Thumbnail: AI-generated editorial illustration. Figures are rounded for readability; some releases may be preliminary or subject to revision.
Leave a Reply